# Collegium Pharmaceutical

Type: Company (COLL)

Source: GetYourBrief — https://getyourbrief.com/entity/collegium-pharmaceutical
Canonical HTML page: https://getyourbrief.com/entity/collegium-pharmaceutical

## Timeline

- **2026-02-26**: FY 2025 Earnings — Wave and Collegium release full-year financial results and 2026 guidance.
- **2026**: Anticipated Filing — Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
- **2025-Q4**: RNA Editing Milestone — WVE-006 demonstrates successful RNA editing in AATD patients.
- **2025-Q2**: DMD Breakthrough — Wave reports industry-leading dystrophin expression for WVE-N531.

## Recent coverage (7 stories, network-wide)

### Collegium Pharma EPS Beats by $0.20; Revenue Grows 6.3% to $199.88M
2026-08-09 18:29:04 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Full story: https://gethealthbrief.com/story/collegium-pharma-q2-2026-earnings-health

### COLL Beats Q2 EPS by $0.20, Stock Gains 1.24% to $29.47
2026-08-09 18:28:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Full story: https://getfinancebrief.com/story/collegium-pharma-q2-2026-earnings-finance

### COLL Q2 EPS Beats by $0.20; Revenue Up 6.3% to $199.88M
2026-08-09 18:28:47 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Full story: https://getbiobrief.com/story/collegium-pharma-q2-2026-earnings-bio

### Mid-Cap Biotech Earnings: Specialized Platforms Outperform in Q4 2025
2026-02-26 22:32:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Full story: https://gethealthbrief.com/story/mid-cap-biotech-q4-2025-earnings-intelligence

### Pharma Earnings: Wave Life Sciences and Collegium Report 2025 Results
2026-02-26 14:29:40 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Full story: https://getfinancebrief.com/story/wave-life-sciences-collegium-2025-earnings-analysis

### Wave Life Sciences and Collegium FY2025 Results Signal RNA and Pain Pivot
2026-02-26 14:28:36 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
Full story: https://getbiobrief.com/story/wave-life-sciences-collegium-fy2025-earnings-analysis

### Wave Life Sciences and Collegium Report 2025 Results Amid RNA Breakthroughs
2026-02-26 14:24:42 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Full story: https://gethealthbrief.com/story/wave-life-sciences-collegium-2025-financials-rna-editing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.